Atherosclerosis in Marek's disease virus infected hypercholesterolemic roosters is reduced by HMGCoA reductase and ACE inhibitor therapy

Cardiovascular Research

Volumn 38, Issue 1, 1998, Pages 237-246

  Lucas, Alexandra ^a,b   Dai, Erbin ^a,b   Liu, Li Ying ^a,b   Nation, Patric N ^b  

^a ROBARTS RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Angiotensin converting enzyme inhibitor; Atherosclerosis; HMGCoA reductase inhibitor; Lymphocyte; Marek's disease virus; White Leghorn roosters

Indexed keywords

CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRAVASTATIN; QUINAPRIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; AVIAN LYMPHOMATOSIS HERPETOVIRUS; BIRD DISEASE; CHICKEN; CHOLESTEROL DIET; CONTROLLED STUDY; HISTOPATHOLOGY; LYMPHOCYTIC INFILTRATION; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ARTERIOSCLEROSIS; CAROTID ARTERIES; CHICKENS; CHOLESTEROL; DISEASE MODELS, ANIMAL; HERPESVIRUS 2, GALLID; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; ISOQUINOLINES; LYMPHOCYTES; MAREK DISEASE; PRAVASTATIN; TETRAHYDROISOQUINOLINES;

EID: 0032051998     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(97)00315-5     Document Type: Article

References (53)

1. [1] Halle AA, DiSciascio G, Massin EK, Wilson RF, Johnson MR, Sullivan HJ, Bourge RC, Kleiman NS, Miller LM, Aversano TR, Wray RB, Hunt SA, Weston MW, Davies RA, Rincon G, Crandall CC, Cowley MJ, Kubo SH, Fisher SG, Vetrovec GW. Coronary angioplasty, atherectomy and bypass surgery in cardiac transplant recipients. J Am Coll Cardiol 1996;26:120-128.
2. [2] Billingham ME. Graft coronary disease: the lesions and the patients. Transplant Proc 1989;21:3665-3666.
3. [3] Sharples LD, Mullins P, Scott JP, Solis E, English TA, Large SR, Schofield PM, Wallwork J. Risk factor analysis for the major hazards following heart transplantation - rejection, infection, and coronary occlusive disease. Transplantation 1991;52:244-252.
4. [4] Helin P, Lorenzen I, Garbarsch C, Matthiessen ME. Arteriosclerosis in rabbit aorta induced by mechanical dilatation. Atherosclerosis 1971;13:319-331.
5. [5] Topol EJ, Leya F, Pinkerton CA, Whitlow PL, Hofling B, Simonton CA, Masden RR, Serruys PW, Leon MB, Williams DO, King SB, Mark DB, Isner JM, Holmes DR, Ellis SG, Lee KL, Keeler GP, Berdan LG, Hinokara T, Califf RM. A comparison of directional atherectomy with coronary angioplasty in patients with coronary artery disease. N Engl J Med 1993;329:221-227.
6. [6] Shi C, Russell ME, Bianchi C, Newell JB, Haber E. Murine model of accelerated transplant atherosclerosis. Circ Res 1994;75:199-207.
7. [7] Wreghit TG, Hakim M, Gray JJ, Kucia S, Cory-Pearce R, Wallwork J, English TAH. A detailed study of cytomegalovirus infections in the first 160 heart/lung transplant recipients at Papworth Hospital, Cambridge England. Transplant Proc 1987;19:2495-2496.
8. [8] Grattan MT, Moreno-Cabral CE, Starnes VA, Oyer PE, Stinson EB, Shumway NE. Cytomegalovirus rejection is associated with cardiac allograft rejection and atherosclerosis. J Am Med Assoc 1989;261:3561-3566.
9. [9] McDonald K, Rector TS, Braunlin TA, Kubo SH, Olvari MT. Association of coronary artery disease in cardiac transplant recipients with cytomegalovirus infection. Am J Pathol 1989;64:359-362.
10. [10] Speir E, Modali R, Huang E-S, Leon MB, Shawl F, Finkel T, Epstein SE. Potential role of human cytomegalovirus and p53 interaction in coronary restenosis. Science 1994;265:391-394.
11. [11] Marx J. CMV-p53 interaction may help explain clogged arteries. Science 1994;265:320.
12. [12] Visser MR, Vercellotti GM. Herpes simplex virus and atherosclerosis. Eur Heart J 1993;14:39-42. Suppl. K.
13. [13] Melnick JL, Adam E, Debakey ME. Cytomegalovirus and atherosclerosis. Eur Heart J 1993;14:30-38. Suppl. K.
14. [14] Melnick JL, Hu C, Burek J, Adam E, DeBakey ME. Cytomegalovirus DNA in arterial walls of patients with atherosclerosis. J Med Virol 1994;42:170-174.
15. [15] Hendrix MGR, Salimans MMM, VanBoven CPA, Bruggeman CA. High prevalence of latently present cytomegalovirus in arterial walls of patients suffering from grade III atherosclerosis. Am J Pathol 1990;136:23.
16. [16] Hendrix MGR, Dormans PHJ, Kitslar P, Bosman F, Bruggeman CA. The presence of cytomegalovirus nucleic acids in arterial walls of atherosclerotic and in atherosclerotic patients. Am J Pathol 1989;134:1151.
17. [17] Fabricant CG, Fabricant J, Minick CR, Litrenta MM. Herpesvirus-induced atherosclerosis in chickens. Fed Proc 1983;42:2476-2479.
18. [18] Benditt EP, Barett T, McDougall JK. Viruses in the etiology of atherosclerosis. Proc Natl Acad Sci USA 1983;80:6386-6389.
19. [19] Minick CR, Fabricant CG, Fabricant J, Litrenta MM. Atheroarteriosclerosis induced by infection with herpes virus. Am J Pathol 1979;96:673-700.
20. [20] Persoons MCJ, Daemen MJAP, Bruning JH, Bruggeman CA. Active cytomegalovirus infection of arterial smooth muscle cells in immunocompromised rats: A clue to herpesvirus-associated atherogenesis. Circ Res 1994;75:214-220.
21. [21] Fabricant CG, Hajjar DP, Minick CR, Fabricant J. Herpesvirus infection enhances cholesterol and cholesteryl ester accumulation in cultured arterial smooth muscle cells. Am J Pathol 1981;105:176-184.
22. [22] Span AHM, Grauls G, Bosman F, Van Boven CPA, Bruggeman CA. Cytomegalovirus infection induces vascular injury in the rat. Atherosclerosis 1992;93:41-52.
23. [23] Libby P, Schwartz D, Brogi E, Tanaka H, Clinton SK. A cascade model for restenosis: A special case of atherosclerosis progression. Circulation 1992;86:47-52. Suppl. III.
24. [24] Ross R, Glomset JA. The pathogenesis of atherosclerosis. N Engl J Med 1976;295:369-377.
25. [25] Ross R, Glomset JA. The pathogenesis of atherosclerosis. N Engl J Med 1976;295:420-425.
26. [26] 4S Study Investigators, Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-1389.
27. [27] Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, Macfarlane PW, McKillop JH, Packard CJ. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301-1307.
28. [28] The CCAIT Study Group, Waters D, Higginson L, Gladstone P, Kimball B, LeMay M, Boccuzzi SJ, Lesperance J. Effect of monotherapy with an HMGCoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. Circulation 1994;89:959-968.
29. [29] Egashira K, Hirooka Y, Kai H, Sugimachi M, Suzuki S, Inou T, Takeshita A. Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia. Circulation 1994;89:2519-2524.
30. [30] Kobashigawa JA, Katznelson S, Laks H, Johnson JA, Yeatman L, Wang XM, Chia D, Terasaki PI, Sabad A, Cogert GA, Trosian K, Hamilton MA, Moriguchi JD, Kawata N, Hage A, Drinkwater DC, Stevenson LW. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 1995;333:621-627.
31. [31] Diet F, Pratt RE, Berry GJ, Momose N, Gibbons GH, Dzau VJ. Increased accumulation of tissue ACE in human atherosclerotic coronary artery disease. Circulation 1996;94:2756-2767.
32. [32] Mancini GBJ, Henry GC, Macaya C, O'Neill BJ, Pucillo AL, Carere RG, Wargovich TJ, Mudra H, Luscher TF, Klibaner MI, Haber HE, Uprichard ACG, Pepine CJ, Pitt B. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. Circulation 1996;94:258-265.
33. [33] Lonn EM, Yusuf S, Jha P, Montague TJ, Teo KK, Benedict CR, Pitt B. Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection. Circulation 1994;90:2056-2069.
34. [34] Pfeffer MA, Braunwald E, Moye L, Basta L, Brown EJ, Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC, Klein M, Lamas G, Packer M, Rouleau J, Rouleau J, Rutherford J, Wertheimer JH, Hawkins CM. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the survival and ventricular enlargement trial. N Engl J Med 1992;327:669-677.
35. [35] Lehmann K, Powell JS. Effect of cilazapril on the proliferative response after vascular damage. J Card Pharm 1993;22:S19-S24. Suppl. 4.
36. [36] Charpiot P, Rolland PH, Friggi A, Piquet P, Scalbert E, Bodard H, Barlatier A, Latrille V, Tranier P, Mercier C, Luccioni R, Calaf R, Garcon D. ACE inhibition with perindopril and atherogenesis-induced structural and functional changes in minipig arteries. Art Thromb 1993;13:1125-1138.
37. [37] Kowala MC, Grove RI, Aberg G. Inhibitors of angiotensin converting enzyme decrease early atherosclerosis in hyperlipidemic hamsters. Fosinopril reduces plasma cholesterol and captopril inhibits macrophage-foam cell accumulation independently of blood pressure and plasma lipids. Atherosclerosis 1994;108:61-72.
38. [38] MARCATOR Study Group, Faxxon DP. Effect of high dose angotensin-converting enzyme inhibition on restenosis: Final results of the MARCATOR study, a multicenter, double-blind, placebo-controlled trial of cilazapril. J Am Coll Card 1995;25:362-369.
39. [39] Desmet W, Vrolix M, De Scheerder I, Van Lierde J, Willems JL, Piessens J. Angiotensin-converting enzyme inhibition with fosinopril sodium in the prevention of restenosis after coronary angioplasty. Circulation 1994;89:385-392.
40. [40] Mehra MR, Ventura HO, Smart FW, Stapleton DD. Impact of converting enzyme inhibitors and calcium entry blockers on cardiac allograft vasculopathy: From bench to bedside. J Heart Lung Transplant 1995;14:8246-249.
41. [41] Veinot JP, Edwards WD, Camrud AR, Jorgenson MA, Homes DR Jr., Schwartz RS. The effects of lovastatin on neointimal hyperplasia following injury in a porcine coronary artery model. Can J Cardiol 1996;12:65-70.
42. [42] Dowell FJ, Hamilton CA, Lindop GB, Reid JL. Development and progression of atherosclerosis in aorta from heterozygous and homozygous WHHL rabbits. Effects of simvastatin treatment. Art Thromb Vasc Biol 1995;15:1152-1160.
43. [43] O'Keefe JH Jr., Stone GW, McCallister BD Jr., Maddex C, Ligon R, Kacich RL, Kahn J, Cavero PG, Hartzler GO, McCallister BD. Lovastatin plus probucol for prevention of restenosis after percutaneous transluminal coronary angioplasty. Am J Cardiol 1996;77:649-652.
44. [44] Weintraub WS, Boccuzzi SJ, Klein JL, Kosinski AS, King SB 3rd, Ivanhoe R, Cedarholm JC, Stillabower ME, Talley JD, DeMaio SJ. Lack of effect of lovastatin on restenosis after coronary angioplasty. Lovastatin restenosis trial study group. N Engl J Med 1994;331:1331-1337.
45. [45] Roth A, Eschar Y, Keren G, Sheps D, Kerbal S, Laniado S, Miller HI, Rubinstein A. Serum lipids and restenosis after successful percutaneous transluminal coronary angioplasty. Am J Cardiol 1994;73:1154-1158.
46. [46] Foley JB, Younger K, Foley D, Kinsella A, Molloy M, Crean PA, Gearty G, Gibney M, Walsh MJ. Lipids and fatty acids and their relationship to restenosis. Catheter Card Diag 1992;25:25-30.
47. [47] Yan WD, Perk M, Chagpar A, Wen Y, Stratoff S, Schneider WJ, Jugdutt BJ, Tulip J, Lucas A. Laser-induced fluorescence: III. Quantitative analysis of atherosclerotic plaque content. Lasers Surg Med 1995;16:164-178.
48. [48] Lucas A, Yue W, Jiang XY, Liu LY, Yan WD, Bauer J, Schneider W, Tulip J, Chagpar A, Dai E, Perk M, Montague P, Garbutt M, Radosavljevic M. Development of an avian model for restenosis. Atherosclerosis 1996;119:17-41.
49. [49] Yan WD, Perk M, Nation PN, Power RF, Liu LY, Jiang XY, Lucas A. Fluorescence spectroscopic detection of virus-induced atherosclerosis. SPIE 1994;2130-11:74-81.
50. [50] Raiteri M, Arnaboldi L, Quarato P, Paoletti R, Fumagalli R, Corsini A. The pharmacology of the statins: the evidence of a direct antiatherosclerotic action. Ann Ital Med Int 1995;10:35S-42S.
51. [51] Clozel M, Kuhn H, Baumgartner HR. ACE inhibition and the vascular intima in hypertension. J Card Pharm 1993;22:S15-S18.
52. [52] Cangelosi MM, Gaudio M, Brancati AM, Leggio F. Blood lipid changes in hypertensive, dyslipidemic patients under long term quinapril treatment. Int Ang 1994;13:65-67.
53. [53] Liu LY, Dai E, Lundstrom Hobman M, Kolodziejczyk D, Lucas A. Animal models of restenosis: Myth or reality. Curr Pharm Design 1996;2:553-584.